Optimizing primary vaccination schedule for premature infants

Optimizing primary vaccination schedule for premature infants - PRIEMA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44869

Enrollment

300

Registered

2018-10-17

Start date

2015-10-22

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunogeniciteit bij prematuren ten aanzien van respons op de vaccinaties uit het RVP en de rotavirusvaccinatie antibody's immunogenicity

Interventions

antibody levels

preterm infants

vaccination

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: preterm infants, stratified in 3 groups (

Exclusion criteria

Exclusion criteria: not willing to let take blood

Design outcomes

Primary

Measure	Time frame
Main study parameter/endpoint * Antibody levels against the regular NIP vaccine components (DTaP, IPV, HIb, HepB and PCV10) at 5 and 12 month of age in preterm infants.	—

Secondary

Measure	Time frame
Secondary study parameters/endpoints * Levels of maternal antibodies at 6 weeks of age * Cellular immunity at 12 month * Timelines of NIP vaccines * Tolerability and vaccine side effects * Rotavirus seroconversion rates and antibody levels at 5 an 12 month of age among those vaccinated	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)